Age-related decline in CD8<sup>+</sup> tissue resident memory T cells compromises antitumor immunity.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39592880.
- Also identified by DOI 10.1038/s43587-024-00746-5.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Aging compromises antitumor immunity, but the underlying mechanisms remain elusive. Here, we report that aging impairs the generation of CD8<sup>+</sup> tissue resident memory T (T<sub>RM</sub>) cells in nonlymphoid tissues in mice, thus compromising the antitumor activity of aged CD8<sup>+</sup> T cells, which we also observed in human lung adenocarcinoma. We further identified that the apoptosis regulator BFAR was highly enriched in aged CD8<sup>+</sup> T cells, in which BFAR suppressed cytokine-induced JAK2 signaling by activating JAK2 deubiquitination, thereby limiting downstream STAT1-mediated T<sub>RM</sub> reprogramming. Targeting BFAR either through Bfar knockout or treatment with our developed BFAR inhibitor, iBFAR2, rescued the antitumor activity of aged CD8<sup>+</sup> T cells by restoring T<sub>RM</sub> generation in the tumor microenvironment, thus efficiently inhibiting tumor growth in aged CD8<sup>+</sup> T cell transfer and anti-programmed cell death protein 1 (PD-1)-resistant mouse tumor models. Together, our findings establish BFAR-induced T<sub>RM</sub> restriction as a key mechanism causing aged CD8<sup>+</sup> T cell dysfunction and highlight the translational potential of iBFAR2 in restoring antitumor activity in aged individuals or patients resistant to anti-PD-1 therapy.
Medical subject headings
- CD8-Positive T-Lymphocytes
- Memory T Cells
- Aging